Oncologia Medica, Dipartimento Uro-Ginecologico, Istituto Nazionale Tumori, Napoli, Italy.
Ther Clin Risk Manag. 2009 Aug;5(4):421-6. doi: 10.2147/tcrm.s4317. Epub 2009 Jun 22.
Epidemiologic analysis reveals that the mortality rate from ovarian cancer is continuously decreasing due to the improvement of surgery and chemotherapy. However, the prognosis of ovarian cancer patients is still unsatisfactory overall considering that only 30% of patients are alive after five years. In fact, although surgery and first-line systemic chemotherapy induces complete and partial response in up to 80% of patients with about a 25% pathological complete remission rate, recurrences occur in the majority of patients. The role of surgery in recurrent disease has been recently studied and many patients can receive an optimal secondary cytoreduction. Most of the recurrent patients are subject to a number of treatment regimens that, although palliative in nature, are also able to prolong survival. Important results have been obtained in particular in platinum-sensitive recurrent disease where a platinum-based chemotherapy is able to prolong progression-free survival and overall survival. Overall, our armamentarium for the treatment of progressive or recurrent ovarian cancer is significantly richer than in the past, and in many patients it is possible to achieve our goal of controlling the chronic behavior of the disease.
流行病学分析显示，由于手术和化疗的改进，卵巢癌的死亡率持续下降。然而，考虑到只有 30%的患者在五年后仍然存活，卵巢癌患者的总体预后仍然不尽如人意。事实上，尽管手术和一线全身化疗使多达 80%的患者达到完全缓解和部分缓解，缓解率约为 25%，但大多数患者仍会复发。最近对手术在复发性疾病中的作用进行了研究，许多患者可以接受最佳的二次细胞减灭术。大多数复发性患者接受了多种治疗方案，尽管这些方案是姑息性的，但也能延长生存时间。在铂类敏感的复发性疾病中取得了重要的结果，铂类化疗能够延长无进展生存期和总生存期。总的来说，我们治疗进展性或复发性卵巢癌的手段比过去丰富得多，在许多患者中，我们有可能实现控制疾病慢性行为的目标。
